The shared services Core will synthesize sialic acid containing ligands of siglecs that are needed for the projects of the Lung Inflammatory Disease- Program of Excellence in Glycosciences (LID-PEG) and other PEGs. The core will accomplish its goals using chemo-enzymatic synthesis technology assembled and in routine use in the Core Leader's laboratory. Compounds targeted for synthesis in the first year will be those needed by the LID-PEG projects. Envisioned applications of the compounds include: 1) assaying the ligand binding activity of recombinant siglec reagents, 2) development of siglec-ligand decorated nanoparticles for targeting leukocytes expressing the corresponding siglec, 3) isolation of siglec counter- receptors, and 4) use as standards for MS/MS identification of glycan fragments related to siglec ligands. The Core will also synthesize compounds to meet the needs of other PEGs, and will engage in collaborative synthesis with carbohydrate chemistry groups within the PEGs for products that can benefit from the Core technology. The Executive Committee of the LID-PEG will periodically review and prioritize the list of glycans to be produced by the Shared Resources Core C. Once produced, compounds will be distributed to the LID-PEG and other PEG projects upon request. Compounds will also be made available to investigators outside the PEGs. The list of compounds available from the Core will be posted online at the LID-PEG web site and (preferably) also at the central PEG website.
This shared resource core will synthesize carbohydrates that are recognized by receptors on immune cells. Nanoparticles decorated with these compounds can carry cargo to immune cells for diagnosis and treatment of inflammatory diseases of the lung and cardiovascular system.
|Kumagai, Tadahiro; Kiwamoto, Takumi; Brummet, Mary E et al. (2018) Airway glycomic and allergic inflammatory consequences resulting from keratan sulfate galactose 6-O-sulfotransferase (CHST1) deficiency. Glycobiology 28:406-417|
|Wei, Yadong; Chhiba, Krishan D; Zhang, Fengrui et al. (2018) Mast Cell-Specific Expression of Human Siglec-8 in Conditional Knock-in Mice. Int J Mol Sci 20:|
|Li, Tao; Hu, Rong; Chen, Zi et al. (2018) Fine particulate matter (PM2.5): The culprit for chronic lung diseases in China. Chronic Dis Transl Med 4:176-186|
|Robida, Piper A; Puzzovio, Pier Giorgio; Pahima, Hadas et al. (2018) Human eosinophils and mast cells: Birds of a feather flock together. Immunol Rev 282:151-167|
|O'Sullivan, Jeremy A; Carroll, Daniela J; Cao, Yun et al. (2018) Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells. J Allergy Clin Immunol 141:1774-1785.e7|
|O'Sullivan, Jeremy A; Wei, Yadong; Carroll, Daniela J et al. (2018) Frontline Science: Characterization of a novel mouse strain expressing human Siglec-8 only on eosinophils. J Leukoc Biol 104:11-19|
|Edgar, Landon J; Kawasaki, Norihito; Nycholat, Corwin M et al. (2018) Targeted Delivery of Antigen to Activated CD169+ Macrophages Induces Bias for Expansion of CD8+ T Cells. Cell Chem Biol :|
|Khoury, Paneez; Bochner, Bruce S (2018) Consultation for Elevated Blood Eosinophils: Clinical Presentations, High Value Diagnostic Tests, and Treatment Options. J Allergy Clin Immunol Pract 6:1446-1453|
|Chen, Zi; Bai, Fang-Fang; Han, Lu et al. (2018) Targeting Neutrophils in Severe Asthma via Siglec-9. Int Arch Allergy Immunol 175:5-15|
|O'Sullivan, Jeremy A; Bochner, Bruce S (2018) Eosinophils and eosinophil-associated diseases: An update. J Allergy Clin Immunol 141:505-517|
Showing the most recent 10 out of 78 publications